We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Walgreens Boots' Retail Business Solid Amid Several Concerns
Read MoreHide Full Article
On Mar 29, we issued an updated research report on Walgreens Boots Alliance, Inc. (WBA - Free Report) .
We are currently looking forward to the company’s modified Rite Aid contract, expected to benefit the company in the long run. The stock carries a Zacks Rank #3 (Hold).
Over the past three months, shares of Walgreens Boots have outperformed the industry. The stock has lost 6.9%, narrower than the industry’s 11.1% decline. We note that the company reported better-than-expected second-quarter fiscal 2018 results, having grossed highest sales in the last eight quarters.
We are encouraged by the company’s consistent sales increase in the Retail Pharmacy International business. Moreover, Walgreens Boots has been gaining traction from a slew of strategic tie-ups, which brought more patients to its U.S. pharmacies.
We are also upbeat about the company’s alliance with Express Scripts, via which, both companies aim to expand respective existing group purchasing efforts. This latest pact is expected to improve Express Scripts’ supply chain and make medicines including biosimilars affordable and accessible to patients.
The above positives apart, Walgreens Boots’ decision to buy a 40% stake in China’s Sinopharm Holding Guoda Drugstores looks promising as that should provide a strong impetus to the company’s worldwide retail pharmacy business. The limited number of Rite Aid stores’ acquisition also impresses us for which, the company has recently secured a regulatory approval.
However, Walgreens Boots faces headwinds in the form of fierce competition and tough industry conditions. Even though the company continues to reap from its growth initiatives, major mass merchants are already advancing with boost in pharmacy businesses and a fair market share.
Notably, a slowdown in generic introduction over the last few years has been affecting Walgreens Boots’ margins. Also, an escalated reimbursement pressure and a generic drug cost inflation have been hampering Walgreens Boots’ margins significantly.
Key Picks
Some better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Edwards Lifesciences Corporation (EW - Free Report) .
athenahealth is a Zacks #1 Ranked player. It has a long-term expected earnings growth rate of 21.5%.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.1%. The stock carries a Zacks Rank #2 (Buy).
Can Hackers Put Money INTO Your Portfolio?
Earlier this year, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Image: Bigstock
Walgreens Boots' Retail Business Solid Amid Several Concerns
On Mar 29, we issued an updated research report on Walgreens Boots Alliance, Inc. (WBA - Free Report) .
We are currently looking forward to the company’s modified Rite Aid contract, expected to benefit the company in the long run. The stock carries a Zacks Rank #3 (Hold).
Over the past three months, shares of Walgreens Boots have outperformed the industry. The stock has lost 6.9%, narrower than the industry’s 11.1% decline. We note that the company reported better-than-expected second-quarter fiscal 2018 results, having grossed highest sales in the last eight quarters.
We are encouraged by the company’s consistent sales increase in the Retail Pharmacy International business. Moreover, Walgreens Boots has been gaining traction from a slew of strategic tie-ups, which brought more patients to its U.S. pharmacies.
Walgreens Boots Alliance, Inc. Price
Walgreens Boots Alliance, Inc. Price | Walgreens Boots Alliance, Inc. Quote
We are also upbeat about the company’s alliance with Express Scripts, via which, both companies aim to expand respective existing group purchasing efforts. This latest pact is expected to improve Express Scripts’ supply chain and make medicines including biosimilars affordable and accessible to patients.
The above positives apart, Walgreens Boots’ decision to buy a 40% stake in China’s Sinopharm Holding Guoda Drugstores looks promising as that should provide a strong impetus to the company’s worldwide retail pharmacy business. The limited number of Rite Aid stores’ acquisition also impresses us for which, the company has recently secured a regulatory approval.
However, Walgreens Boots faces headwinds in the form of fierce competition and tough industry conditions. Even though the company continues to reap from its growth initiatives, major mass merchants are already advancing with boost in pharmacy businesses and a fair market share.
Notably, a slowdown in generic introduction over the last few years has been affecting Walgreens Boots’ margins. Also, an escalated reimbursement pressure and a generic drug cost inflation have been hampering Walgreens Boots’ margins significantly.
Key Picks
Some better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Edwards Lifesciences Corporation (EW - Free Report) .
Bio-Rad Laboratories sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. It has a long-term expected earnings growth rate of 21.5%.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.1%. The stock carries a Zacks Rank #2 (Buy).
Can Hackers Put Money INTO Your Portfolio?
Earlier this year, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>